Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure Mar 9, 2015 7:00 am EDT
Trevena CEO to Present at the Cowen and Company 35th Annual Health Care Conference Feb 24, 2015 7:00 am EST
Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain Feb 9, 2015 7:00 am EST
TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure Feb 3, 2015 7:00 am EST
Trevena Initiates Second Phase 2b Study of TRV130 for Acute Postoperative Pain Jan 6, 2015 4:01 pm EST
Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters’ Option to Purchase Additional Shares Dec 10, 2014 4:01 pm EST